Literature DB >> 6884417

Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination.

A Roux, A Le Liboux, B Delhotal, J Gaillot, B Flouvat.   

Abstract

The pharmacokinetics of acebutolol and hydrochlorothiazide (HCT) alone or in combination were studied in 12 healthy subjects in a cross over study. Acebutolol and diacetolol (the main metabolite) in plasma and urine were determined by HPLC and hydrochlorothiazide by GLC. The main pharmacokinetic parameters of acebutolol did not differ significantly: AUC 4492 +/- 272 micrograms l-1h given alone versus 4118 +/- 354 micrograms l-1h with HCT, half-life (7,69 +/- 0,32 h vs 8,10 +/- 0,72 h) and renal clearance (13,1 +/- 0,5 lh-1 vs 13,8 +/- 0,9 lh-1), respectively. There was no difference in diacetolol pharmacokinetics. HCT values were not significantly different: AUC 784 +/- 48 micrograms l-1h given alone and 720 +/- 42 micrograms l-1h with acebutolol, t 1/2 (4,79 +/- 0,37 h vs 4,73 +/- 0,43 h). The renal clearance was slightly higher when HCT was given with acebutolol (26,2 +/- 2,6 vs 20,3 +/- 2,1 lh-1, p less than 0,05). This increase, observed during the first four hours, was probably due to competition between the drugs for binding to red blood cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6884417     DOI: 10.1007/bf00607091

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  Individual factors influencing the response to a beta-adrenergic blocking agent given alone and in combination with a diuretic on arterial hypertension.

Authors:  O L Pedersen; E Mikkelsen
Journal:  Eur J Clin Pharmacol       Date:  1979-11       Impact factor: 2.953

2.  Dose-dependent acebutolol disposition after oral administration.

Authors:  P J Meffin; R A Winkle; F A Peters; D C Harrison
Journal:  Clin Pharmacol Ther       Date:  1978-11       Impact factor: 6.875

3.  Antihypertensive effect of atenolol alone or combined with chlorthalidone in patients with essential hypertension.

Authors:  M Velasco; J Guevara; J Morillo; A Ramírez; A Urbina-Quintana; O Hernández-Pieretti
Journal:  Br J Clin Pharmacol       Date:  1980-05       Impact factor: 4.335

4.  Pharmacokinetics of atenolol in hypertensive subjects with and without co-administration of chlorthalidone.

Authors:  E Riva; P L Farina; R Sega; G Tognoni; W Bastain; J McAinsh
Journal:  Eur J Clin Pharmacol       Date:  1980-05       Impact factor: 2.953

5.  Antihypertensive activity of a fixed combination of oxprenolol and chlorthalidone in mild to moderate arterial hypertension.

Authors:  M Motolese; E Agabiti-Rosei; A Carotti; P Innocenti; C Montervino; E Solinas; M Toso; G Muiesan
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1980

6.  [Sensitive method for the determination of acebutolol and its N-acetyl metabolite in biological media by high performance liquid chromatography and fluorescence detection].

Authors:  A Roux; B Flouvat
Journal:  J Chromatogr       Date:  1978-12-01

7.  Acebutolol metabolite plasma concentration during chronic oral therapy.

Authors:  R A Winkle; P J Meffin; W B Ricks; D C Harrison
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

8.  Fixed combination of sotalol and hydrochlorothiazide in the treatment of uncomplicated hypertension.

Authors:  A Jäättelä
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

9.  A pharmacokinetic study of acebutolol in aged subjects as compared to young subjects.

Authors:  A Roux; J F Henry; Y Fouache; N P Chau; M P Hervy; F Forette; J P Bourdarias; B Flouvat
Journal:  Gerontology       Date:  1983       Impact factor: 5.140

10.  Bioavailability and disposition of metoprolol and hydrochlorothiazide combined in one tablet and of separate doses of hydrochlorothiazide.

Authors:  L Jordö; G Johnsson; P Lundborg; B A Persson; C G Regärdh; O Rönn
Journal:  Br J Clin Pharmacol       Date:  1979-06       Impact factor: 4.335

View more
  4 in total

1.  Column-switching high-performance liquid chromatographic (HPLC) determination of hydrochlorothiazide in rat, dog, and human plasma.

Authors:  B S Kuo; A Mandagere; D R Osborne; K K Hwang
Journal:  Pharm Res       Date:  1990-12       Impact factor: 4.200

2.  Exploring the Feasibility of Biowaiver Extension of BCS Class III Drugs with Site-Specific Absorption Using Gastrointestinal Simulation Technology.

Authors:  Le Sun; Jin Sun; Zhonggui He
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

3.  Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics.

Authors:  P O'Grady; K F Yee; R Lins; B Mangold
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

4.  A comparative study of the pharmacokinetics and pharmacodynamics of atenolol, hydrochlorothiazide and amiloride in normal young and elderly subjects and elderly hypertensive patients.

Authors:  K Sabanathan; C M Castleden; H K Adam; J Ryan; T J Fitzsimons
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.